February 17, 2023 06:41 AM ESTUpdated 04:46 PM
R&D
Pharma

Up­dat­ed: Pfiz­er drops half of par­tic­i­pants from Ly­me tri­al af­ter say­ing re­search con­trac­tor broke rules

Amber Tong

Senior Editor

Drew Armstrong

Executive Editor

Pfiz­er is re­mov­ing about sev­er­al thou­sand US par­tic­i­pants from a Phase III Ly­me dis­ease tri­al be­cause a con­trac­tor run­ning some clin­i­cal sites vi­o­lat­ed qual­i­ty stan­dards …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Eu­ro­pean drug reg­u­la­tor re­jects Alzheimer's drug Leqem­bi, cit­ing safe­ty con­cerns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times